Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We’re delighted and proud to be a founder investor in this great company. Onward!

The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis. These debilitating diseases affect millions of patients worldwide and represent areas of significant unmet medical need.

Under the terms of both agreements, Relation will receive a total upfront payment from GSK of $45 million which comprises an equity investment of $15 million. In addition, Relation will be eligible to receive success-based collaboration payments of up to $63 million, as well as potential preclinical, development, commercial, and sales milestone payments averaging $200 million per target across both deals, along with tiered royalties on net sales of products.

Relation will lead observational studies to generate two unique functional disease data sets and Relation’s Lab-in-the-Loop platform will analyse this data by integrating human genetics, single-cell multi-omics directly from human tissue, functional assays, and machine learning to discover novel disease targets. This approach minimises the risk of clinical failure by ensuring targets are robustly validated before entering the clinic. Relation will apply its platform to a number of related fibrotic conditions and also osteoarthritis. GSK will have worldwide development and commercialisation rights to any resulting targets.

Press release found here

Endpoints article found here

Times article found here